Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children
| Autor: | Francesca Rovere, Rossella Paparazzo, Natalia Maximova, Davide Zanon, Giulia Schillani, Alessandra Maestro |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Adolescent medicine.medical_treatment Recombinant Fusion Proteins Hematopoietic stem cell transplantation Receptors Fc Internal medicine medicine Humans Platelet Adverse effect Child Hematology Romiplostim business.industry Platelet Count Hematopoietic Stem Cell Transplantation Allografts Thrombocytopenia Surgery Transplantation Thrombopoietin Secondary thrombocytopenia Female Stem cell business medicine.drug |
| Zdroj: | International journal of hematology. 102(5) |
| ISSN: | 1865-3774 |
| Popis: | The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11 years), with platelet counts below 10 × 10(9)/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink